Redeye comments on Verve Group’s Q3 2024 results, which exceeded expectations in terms of sales.
Redeye comments on MindArk’s Q3 results, which were weaker than expected in both sales and profitabi...
Redeye provides a more in-depth review of AcouSort’s Q3 report, which did not include any major supr...
Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation stud...
Redeye has revised its forecast following TH1NG’s Q3 2024 report, where sales declined y/y due to th...
Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 27 november att bolaget har testat ...
STENOCARE announced on November 26th the STENOCARE 3.
Redeye provides a brief comment on Pepaxti's market access in Italy.
Försäljningsmässigt blev tredje kvartalet svagare än vi prognosticerat men resultatmässigt starkare.
Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s plann...
Redeye shares its initial take on TH1NG’s Q3 report, in which revenues were in line with our modest ...
SABCS (San Antonio Breast Cancer Symposium) is a major annual US cancer conference, and this year, B...
Redeye comments on Maximum Entertainment’s Q3-results which were weaker than expected.
Educational day with presentations from core holdings DP Patterning: small initial investment, large...
Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day.
Redeye provides a note about CLS’s TO7B outcome.
Today Absolent announced that Anders Hülse has been appointed new CEO and President of the group.
Vaxxa är ett e-handelsbolag som driver en digital auktionstjänst, där bolaget syftar till att erbjud...
Redeye comments on Freemelt’s agreement with another leading global orthopedic implant OEM.
The largest office transaction YTD in Europe adds ~40% to topline Share issue at Q3 EPRA NRV a clear...